Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CZAR-1
2024-511929-60-00Phase 2Authorised
- Sponsor
- University Hospital Ulm
- Start
- Oct 2024
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised trial in Waldenström macroglobulinemia (WM) comparing Carfilzomib + Ibrutinib with Ibrutinib monotherapy (2 arms). Primary endpoint: Complete Remission or Very Good Partial Remission at 12 months. Planned start Oct 2024; status: authorised.
02
Drugs
carfilzomibibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on 2024-511929-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511929-60-00.